^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KUR-501
i
Other names: KUR-501, CMD-501, CAR-NKT therapy, CAR.GD2-IL-15 NKTs, Chimeric antigen receptors natural killer T-cells (CAR-NKT) therapy, GINAKIT cells, GD2-CAR, GD2-CAR NKT cells, CAR-modified NKT-cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Athenex, Baylor College of Medicine, Texas Children’s Hospital
Drug class:
GD2 ganglioside inhibitor
Related drugs:
3ms
GINAKIT2: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (clinicaltrials.gov)
P1, N=70, Recruiting, Baylor College of Medicine | Trial primary completion date: Jul 2025 --> Dec 2027
Trial primary completion date
|
KUR-501
11ms
PRDM1 is a key regulator of the natural killer T-cell central memory program and effector function. (PubMed, Cancer Immunol Res)
In contrast, shRNA-mediated PRDM1 knockdown preserved effector function while promoting central memory differentiation, resulting in GD2.CAR NKTs with potent in vivo antitumor activity. Thus, we have identified PRDM1 as a regulator of NKT memory differentiation and effector function that can be exploited to improve the efficacy of NKT-based cancer immunotherapies.
Journal
|
GZMB (Granzyme B) • PRDM1 (PR/SET Domain 1)
|
KUR-501
1year
GINAKIT2: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children with Neuroblastoma (clinicaltrials.gov)
P1, N=54, Recruiting, Baylor College of Medicine | N=36 --> 54
Enrollment change
|
KUR-501
over2years
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. (PubMed, Nat Med)
No dose-limiting toxicities occurred; one patient experienced grade 2 cytokine release syndrome that was resolved by tocilizumab. Additionally, their anti-tumor activity may be enhanced by targeting BTG1. ClinicalTrials.gov registration: NCT03294954 .
P1 data • Journal
|
IL15 (Interleukin 15)
|
Actemra IV (tocilizumab) • KUR-501
Share via
